Adolescent females with NAFLD and PCOS have an adverse metabolic phenotype compared with other females and males

Short Title: Adverse metabolic impact of NAFLD combined with PCOS

Oyekoya T Ayonrinde^{1,4}, Leon A Adams^{1,5}, Dorota A Doherty⁶, Trevor A Mori¹, Lawrence J Beilin¹, Wendy H Oddy⁷, Martha Hickey^{8,9}, Deborah M Sloboda¹⁰, John K Olynyk^{2-4,11}, Roger Hart⁶.

¹School of Medicine and Pharmacology, The University of Western Australia, Perth, WA, Australia, ²Department of Gastroenterology and Hepatology, Fiona Stanley Hospital, Murdoch, WA, Australia, ³Department of Gastroenterology, Fremantle Hospital, WA, Australia, ⁴Faculty of Health Sciences, Curtin University, Bentley, WA, Australia, ⁵Liver Transplantation Unit, Sir Charles Gairdner Hospital, Nedlands WA, Australia, ⁶School of Women's and Infants' Health, The University of Western Australia, Subiaco, WA, Australia, ⁷Telethon Institute for Child Health Research, Centre for Child Health Research, The University of Western Australia, Subiaco, WA, Australia ⁸Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, VIC, Australia, ⁹Royal Women's Hospital, Melbourne, VIC, Australia, ¹⁰Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton ON, Canada, ¹¹Murdoch University, Murdoch, WA, Australia

Corresponding Author

Dr Oyekoya T. Ayonrinde

Department of Gastroenterology and Hepatology

Fiona Stanley Hospital

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1111/jgh.13241](https://doi.org/10.1111/jgh.13241)

102 - 118 Murdoch Drive

Murdoch 6150

Australia

Tel: +61861522827

E-mail oyekoya.ayonrinde@uwa.edu.au

Abstract word count = 250

Manuscript word count = 3054 (excluding references); 50 references

Number of tables = 2

Number of figures = 0

The authors have no conflict of interest to disclose in relation to this manuscript

Intellectual input: OTA (study design, data acquisition, data analysis, manuscript preparation), LAA (study design, data acquisition, manuscript review), DAD (study design, data analysis, manuscript review), TAM (data acquisition, manuscript review), LJB (data acquisition, manuscript review), WHO (data acquisition, manuscript review), MH (study design, data acquisition, manuscript review), DS (Data acquisition, manuscript review), JKO (study design, data acquisition, manuscript review), RH (study design, data acquisition, manuscript review).

Grant Funding: This work was supported by the National Health and Medical Research Council [project grants (403968, 634445, 353514, 403981, and 634445), a postgraduate scholarship to Oyekoya T. Ayonrinde (404166), National Health and Medical Research Council Practitioner Fellowships to Martha Hickey (1058935) and to John K. Olynkyk

(1042370) and a research fellowship to Trevor A. Mori, the Gastroenterology Society of Australia (Astra Zeneca Career Development Award to Leon A. Adams), the Fremantle Hospital Medical Research Foundation (medical research grant), and a University of Western Australia Ada Bartholomew grant.

Author Manuscript

Abbreviations

NAFLD, Nonalcoholic fatty liver disease; PCOS, polycystic ovary syndrome; NIH, National Institutes of Health; NASH, nonalcoholic steatohepatitis; BMI, body mass index; SHBG, sex hormone binding globulin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transpeptidase; HDL-C, high-density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; HOMA-IR, homeostasis model assessment for insulin resistance; IQR, interquartile range; CI, confidence interval .

Abstract

Background and aims: Nonalcoholic fatty liver disease (NAFLD) and polycystic ovary syndrome (PCOS) share risk associations of adiposity and insulin resistance. We examined the impact of a PCOS diagnosis on the metabolic phenotype of adolescent girls with NAFLD and compared this to girls without PCOS or NAFLD and to age-matched boys.

Methods: Community-based adolescents from the Raine Cohort participated in assessments for NAFLD (572 girls and 592 boys) and PCOS (244 girls). 199 girls attended both assessments.

Results: Amongst the 199 girls, PCOS was diagnosed in 16.1% and NAFLD in 18.6%. NAFLD was diagnosed in 10.1% of the boys. NAFLD was more prevalent in girls with PCOS than girls without PCOS (37.5% vs. 15.1%, $p=0.003$). Girls with NAFLD plus PCOS had greater adiposity (waist circumference, body mass index, suprailiac skinfold thickness [SST], serum androgens, high-sensitivity C-reactive protein (hsCRP), ferritin, homeostasis model assessment for insulin resistance (HOMA-IR), and lower serum sex hormone binding globulin levels than girls with NAFLD without a PCOS diagnosis (all $p<0.05$). Girls with NAFLD plus PCOS had similar adiposity, HOMA-IR and adiponectin levels to boys with NAFLD, but more adiposity, serum leptin and HOMA-IR than both girls and boys without NAFLD. PCOS (OR 2.99, 95% CI 1.01-8.82, $P=0.048$) and SST (OR 1.14, 95% CI 1.08-1.20, $p<0.001$) independently predicted NAFLD in adolescent girls, however serum androgens and HOMA-IR levels did not.

Conclusions: Adolescent girls with NAFLD plus PCOS have a similar metabolic phenotype to boys with NAFLD. Increasing SST and pre-existing PCOS independently predict NAFLD in adolescent girls.

Keywords

Nonalcoholic fatty liver disease, polycystic ovary syndrome, community, obesity, testosterone, Raine study, insulin resistance, C-reactive protein.

Author Manuscript

Introduction

Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disorder in adolescents affecting up to 17 percent of adolescents^{1,2}. A diagnosis of NAFLD confers increased risk of type 2 diabetes, atherosclerotic cardiovascular disease³, cirrhosis or liver cancer in some individuals⁴. Similarly, the polycystic ovary syndrome (PCOS) is the most common endocrine disorder of women in their reproductive years⁵ and is associated with an adverse cardiometabolic risk^{6,7}. NAFLD and PCOS are both associated with features of the metabolic syndrome^{1,6,8}. NAFLD has been described as the hepatic manifestation⁹ and PCOS proposed as the ovarian manifestation of the metabolic syndrome¹⁰.

PCOS is characterised by menstrual irregularity and hyperandrogenism, and presence of multiple ovarian follicles on ultrasound examination included in the Rotterdam diagnostic criteria^{5,11-13}. The National Institutes of Health (NIH) criteria do not rely on the presence of an ultrasound appearance of a polycystic ovary^{11,14}. PCOS has a prevalence of 8.7-17.8% in young women aged 27-34 years¹⁵. Up to 65% of women with PCOS have insulin resistance and features of the metabolic syndrome, with the risks being highest in obese women¹⁶. We have shown in the Western Australian Pregnancy Cohort (Raine) Study, that girls with PCOS, particularly if overweight, had a higher prevalence of features of the metabolic syndrome (35.3% using NIH criteria and 26.2% using Rotterdam criteria) than girls without PCOS (15.4%)⁶.

Women with PCOS combined with NAFLD may be at increased risk of non-alcoholic steatohepatitis (NASH), the more severe subtype of NAFLD⁸. Several heterogeneous, mainly

clinic-based studies, using different PCOS and NAFLD diagnostic criteria, combinations of serum transaminase, fatty liver index, ultrasound features and body mass index (BMI) in women of various ages have reported up to 42-73% prevalence of NAFLD in individuals with PCOS¹⁷⁻²⁴ and recommended screening for NAFLD in females diagnosed with PCOS. By contrast, there is a paucity of literature regarding PCOS in NAFLD populations. Over half of adult women with PCOS are obese¹⁶. Furthermore, approximately half of all lean women with PCOS may be insulin resistant²⁵. However, NAFLD and transaminase elevations are rare in lean young women with PCOS and insulin resistance²⁶.

There is a close association between NAFLD and an increased risk of PCOS in females of reproductive age²⁷. Obese women commonly have higher serum free testosterone, serum insulin, and insulin resistance with increasing severity of NAFLD²⁸. Baranova and colleagues have proposed a role of androgen-reliant pro-apoptotic pathways, associated with elevated serum levels of the apoptotic biomarker M30, on NAFLD severity in patients with coexisting NAFLD and PCOS compared to controls with NAFLD without PCOS²⁹. Sex differences, possibly related to androgenic effects on liver histology, have also been described in NAFLD, with distinct histopathological features termed type 2 NASH characterised by steatosis, portal inflammation and portal fibrosis predominantly seen in male children³⁰. Further, NAFLD in adolescent males has a more adverse metabolic phenotype and severity than NAFLD in adolescent females¹. However, the relationship between sex hormones and metabolic syndrome-associated disorders, such as NAFLD, is not well understood. Hyperinsulinemia, seen with NAFLD and PCOS, decreases hepatic production of sex hormone binding globulin (SHBG), prolonging the metabolic clearance of testosterone, thus increasing testosterone

bioavailability³¹. Whilst increased androgen bioavailability has been reported in females with PCOS-associated NAFLD^{22,31}, the role of androgens in the pathogenesis of NAFLD in individuals with PCOS is inadequately understood^{32,33}. Nevertheless, an association between high levels of serum estrogen and free testosterone, PCOS and insulin resistance has been described in women with PCOS^{32,33}. Reduced SHBG levels are present in individuals with metabolic syndrome³⁴, PCOS^{33,35-37}, PCOS-associated NAFLD³⁶, type 2 diabetes mellitus³⁷, insulin resistance^{36,37}, obesity³⁸ and NAFLD³⁹, while estradiol has been considered protective against NAFLD⁴⁰. An association between metabolic risk, particularly obesity, in brothers and fathers of females with PCOS has been reported^{41,42}. This finding makes it tempting to speculate that women with PCOS may have an androgen-related genetic vulnerability that confers a metabolic profile, including NAFLD, resembling that of males. The phenotype of NAFLD in females with coexisting PCOS has not previously been systematically compared with NAFLD in males, despite the androgen excess in females with PCOS.

Aims, Materials and Methods

We aimed to determine the prevalence of PCOS in adolescent girls with NAFLD, and to compare the phenotypic features of adolescent girls with NAFLD plus PCOS against boys with NAFLD. We hypothesised that adolescent girls with NAFLD plus PCOS would have metabolic similarities comparable to adolescent boys with NAFLD.

Study participants

Participants were recruited from the Western Australian Pregnancy Cohort (Raine) Study (www.rainestudy.org.au) which was designed to measure the relationships between early life

events and subsequent health and behaviour⁴³. Nearly 2900 women at 18 weeks gestation in Perth, Western Australia, were recruited into the Raine study between 1989 and 1991, and delivered 2,868 live born children⁴³. Detailed anthropometric, cardiovascular, metabolic and endocrine measurements were obtained during surveys at ages 1, 2, 3, 5, 8, 10, 14 and 17 years. The Study was approved by the Human Research Ethics Committee of Princess Margaret and King Edward Memorial Hospitals. Adolescent participants and their parent or guardian provided written informed consent.

An unselected subset of 244 adolescent girls from the Raine Study volunteered to participate in an assessment of reproductive function. The majority of participants were at least two years post-menarche (mean age 15.3 [standard deviation 0.5] years). Timing of menarche was prospectively determined from responses in serial questionnaires. Additionally, 578 adolescent girls and 592 adolescent boys were examined for the presence of NAFLD at 17 years of age. Assessment included detailed questionnaires, anthropometry (weight, height, waist circumference, skinfold thickness), cardiovascular examination (blood pressure and pulse), pelvic ultrasound, abdominal ultrasound (liver, subcutaneous and visceral fat) and fasting blood tests. Data from the 17-year assessment, including the methodology for blood pressure measurement and ultrasound examination for diagnosing fatty liver, subcutaneous, and visceral adipose thickness, have previously been published¹. BMI was calculated as weight (kg) divided by the square of height (m²). Homeostasis model assessment for insulin resistance (HOMA-IR) score was calculated as: $\text{HOMA-IR score} = [\text{Fasting insulin } (\mu\text{U/mL}) \times \text{Fasting glucose (mmol/L)}] / 22.5$. Obesity was defined according to (a) age and gender-adjusted BMI criteria described by Cole et al.⁴⁴, (b) The metabolic syndrome was defined

according to age and gender-specific criteria of the International Diabetes Federation, including obesity as waist circumference greater than 80 cm in females⁴⁵. Two hundred and one girls attended assessments for both PCOS and NAFLD. Two participants were excluded from analyses due to inadequate diagnostic data for PCOS. NAFLD was diagnosed with liver ultrasound using a validated protocol⁴⁶ that provides high sensitivity and specificity for the histologic diagnosis of fatty liver. Excessive alcohol consumption was excluded, consistent with recent guidelines⁴. Abdominal (subcutaneous and visceral) adipose thickness was measured with ultrasound, using a previously described protocol with criteria that correlate closely with compartmental adipose areas and cardio-metabolic risk factors^{1,46-48}.

Pelvic ultrasound was used to describe ovarian morphology, as previously described⁶. Participant study visits for PCOS assessment were scheduled for the second, third, fourth, or fifth day of the adolescent girl's menstrual cycle in order to ensure that blood sampling for sex hormones occurred during the early follicular phase, with visits timed between 3:30 PM and 4:30 PM. The girls recorded all episodes of menstrual bleeding and spotting over the next 90 days in a menstrual diary. Details of the assessments, including androgen assays have previously been published⁴⁹. Plasma concentrations of SHBG and androgens [total testosterone, androstenedione and dihydroepiandrosteronedione (DHEAS)] were measured during the early follicular phase of the menstrual cycle. Total testosterone was measured using a previously validated commercially available double antibody radioimmunoassay and adapted to improve sensitivity by using larger sample volume or longer incubation (DSL-4100, Beckman, Australia). The lower limit of sensitivity was 347 pmol/l and the inter-assay and inter-patient coefficients of variation were 6 and 15%, respectively, at the 1 nmol/l

concentration. SHBG concentrations were determined using a non-competitive liquid-phase radioimmunoassay (68562, Orion Diagnostica, Espoo, Finland). Concentrations of DHEAS (DSL-2700, Beckman, Australia) and androstenedione (DSL-4200, Beckman, Australia) were determined using commercial radioimmunoassay. Circulating free testosterone concentrations were calculated from the measured total testosterone and SHBG concentrations using the Vermeulen equation assuming a standard albumin concentration, as previously described⁴⁹. Boys did not have contemporaneous determination of sex hormones. PCOS was defined using NIH criteria¹¹, which have been demonstrated to be more strongly associated with established cardiovascular risk than the Rotterdam criteria⁶ and ovarian size and morphology have been shown to have limited diagnostic use for PCOS in the study population⁴⁹.

During the 17-year cross-sectional assessment serum from blood obtained after overnight fasting was analysed for glucose, insulin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), triglycerides, high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), ferritin, high sensitivity C-reactive protein (hsCRP), adiponectin, and leptin levels. All assays were performed at an accredited central laboratory (PathWest Laboratories, Perth, Western Australia). Serum ALT levels greater than 30 U/L in females were considered elevated in accordance with the reference laboratory. Testosterone levels greater than the 75th percentile were considered raised. Girls with NAFLD concomitant with PCOS are henceforth referred to as having NAFLD plus PCOS.

Statistical Analysis

Continuous descriptive data are presented as means and standard deviations (SD) for normally distributed data and as medians and interquartile ranges (IQRs) for non-normally distributed data. Categorical variables are reported as frequency distributions. The main outcome variables were the presence or absence of NAFLD and PCOS and severity of steatosis in NAFLD. Univariate analyses were performed, comparing girls with NAFLD plus PCOS versus girls with NAFLD without PCOS; girls with NAFLD plus PCOS versus boys with or without NAFLD. Differences in continuous variables were examined using independent t-tests or one-way analysis of variance with the Bonferroni adjustment for normally distributed variables and the Mann-Whitney U tests or Kruskal-Wallis tests as appropriate for non-normally distributed data. Univariate comparisons of categorical variables between the groups used the chi-square tests or Fisher's exact tests. Multivariable logistic regression modelling was used to determine independent predictors of PCOS in adolescent girls. Covariates included NAFLD diagnosis, suprailiac skinfold thickness, serum SHBG, free testosterone, hsRCP and homeostasis model assessment for insulin resistance (HOMA-IR). The covariate effects of variables in the predictive models for NAFLD were summarized using odds ratios (OR) and their 95% confidence intervals (CI). Data were analyzed with IBM SPSS, version 20.0 (IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp.). All hypotheses tests were two-sided and p-values <0.05 were interpreted as statistically significant.

Results

Prevalence and Metabolic Associations of NAFLD and PCOS

The prevalence of NAFLD in girls overall was 37/199 (18.6%). NAFLD combined with a diagnosis of PCOS was present in 6% (12/199) of girls studied and was characterised by significantly greater adiposity (weight, BMI, waist circumference, subcutaneous fat thickness) in comparison to girls with NAFLD alone or without a NAFLD diagnosis (all $p < 0.05$, Table 1). NAFLD was more prevalent in girls with PCOS than in girls without PCOS (37.5% vs. 15.1%, $p = 0.003$). There was a non-significant greater prevalence of NAFLD with moderate-severe steatosis in girls with NAFLD plus PCOS compared with those with NAFLD without PCOS (25% vs. 3.8%, $p = 0.08$). Comparing girls with moderate-severe steatosis against girls with absent or mild steatosis, the mean serum free testosterone and free androgen index were higher (39.17 pmol/L vs 19.47 pmol/L, $p = 0.003$ and 9.51 vs 3.26, $p < 0.001$ respectively) while the SHBG level was lower (18.35 vs 52.95, $p = 0.009$). Girls with NAFLD combined with PCOS had greater adiposity (apart from visceral adiposity) than other girls and were also more insulin resistant and had higher serum GGT, hsCRP and androgen levels than those with NAFLD alone or without NAFLD (Table 1).

PCOS was diagnosed using the NIH criteria in 32/199 (16.1%) of the adolescent girls studied. Overall, girls with PCOS appeared to have a greater mean (SD) BMI [26.1 (6.0) kg/m^2 vs. 22.6 (3.5) kg/m^2] and waist circumference [84.4 (15.5) cm vs. 76.6 (9.0) cm] (both $p < 0.001$), serum free testosterone levels [38.0 (18.2) pmol/L vs. 16.5 (7.5) pmol/L], leptin [38.8 (29.2) $\mu\text{g/L}$ vs. 29.3 (18.8) $\mu\text{g/L}$] and higher median (IQR) hsCRP [1.3 (0.4-4.2) mg/L vs. 0.6 (0.3-1.6) mg/L] and HOMA-IR [2.1 (1.2-3.4) vs. 1.5 (1.1-2.3), (all $p < 0.05$)], but similar ALT, AST, triglycerides, HDL-C, LDL-C and adiponectin levels in comparison to girls without

PCOS. However, girls with PCOS plus NAFLD had greater adiposity, serum hsCRP, GGT and insulin but similar androgen levels to those with PCOS without NAFLD (Table 1).

NAFLD, PCOS and Serum Transaminase Levels

An elevated serum ALT level (greater than 30U/L), was observed in 25% of those girls with NAFLD plus PCOS, 4% of those with NAFLD without a diagnosis of PCOS, and 4% of girls with neither a diagnosis of NAFLD nor PCOS, and was 0% in girls with PCOS without NAFLD ($p=0.03$).

Testosterone and SHBG levels

Serum androgen measures were higher and SHBG levels were lower in girls with NAFLD plus PCOS, compared with girls with NAFLD without a diagnosis of PCOS ($P < 0.001$ for all, Table 1). Girls with moderate-severe steatosis had lower serum SHBG (18.4 [7.5] nmol/L vs. 52.9 [26.2] nmol/L, $p=0.009$) and greater serum free testosterone (39.2[20.8] pmol/L vs. 19.7[12.5] pmol/L, $p=0.003$) compared with girls with mild or absent steatosis.

Comparison of Girls with NAFLD plus PCOS versus Males

Adiposity (weight, waist circumference, BMI, visceral fat thickness, subcutaneous fat thickness and suprailiac skinfold thickness), fasting lipids, glucose and adiponectin levels of adolescent girls with NAFLD plus PCOS were similar to those of boys with NAFLD ($p > 0.05$, Table 1). However, adolescent boys with NAFLD had higher systolic blood pressure, serum ALT and AST levels, but lower serum leptin and hsCRP than girls with PCOS plus NAFLD ($p < 0.05$, Table 1). Girls with NAFLD plus PCOS had significantly

greater HOMA-IR, hsCRP, leptin and adiposity (except visceral fat) than boys who did not have NAFLD ($p < 0.05$, Table 1).

Metabolic syndrome in girls with NAFLD plus PCOS

Components of the metabolic syndrome were significantly more prevalent in girls with NAFLD plus PCOS than in the other groups of adolescents apart from boys with NAFLD (Table 1). Abdominal obesity and low HDL cholesterol were the most common metabolic abnormalities.

Prediction of NAFLD in Adolescent Girls

In univariate analysis, PCOS, adiposity, serum GGT, triglycerides, HDL-C and HOMA-IR were associated with NAFLD. Androgen measures were not associated with NAFLD (Table 2). Using multivariable logistic regression analysis, the independent predictors of NAFLD in adolescent girls were a PCOS diagnosis (OR 2.99, 95% CI 1.01-8.82, $P = 0.048$) and suprailiac skinfold thickness (OR 1.14, 95% CI 1.08-1.20, $p < 0.001$). Though associated with NAFLD (OR 1.44, 95% CI 1.12-1.86, $p = 0.004$), HOMA-IR did not independently predict NAFLD in adolescent girls after adjusting for PCOS and suprailiac skinfold thickness. Serum ALT did not predict girls with NAFLD combined with PCOS.

Discussion

In this population-based study we have shown a high prevalence of both NAFLD and PCOS in adolescent girls (18.6% and 16.1%, respectively). Girls with NAFLD combined with PCOS had more adiposity and adiposity-related adverse metabolic features than those with

NAFLD alone or girls without NAFLD. Serum free testosterone, ferritin, hsCRP, insulin and HOMA-IR levels were higher, while serum SHBG levels were lower in girls with NAFLD plus PCOS compared with those with NAFLD without concomitant PCOS. A PCOS diagnosis and adiposity determined by suprailiac skinfold thickness, but not androgen levels or HOMA-IR independently predicted NAFLD. Thus, the coexistence of PCOS with NAFLD may identify girls at an increased risk for progressive liver disease and adverse metabolic outcomes by virtue of adiposity but unrelated to androgen levels.

We have previously reported significant gender differences in metabolic risk factors between adolescent boys and girls in the Raine Study. Boys diagnosed with NAFLD had more severe liver steatosis and more adverse metabolic risk factors for future type 2 diabetes mellitus and cardiovascular disease than girls with NAFLD¹. In the current study, girls with NAFLD combined with PCOS had similar adiposity (weight, waist circumference, BMI and subcutaneous fat) to boys with NAFLD. Adiposity in girls with NAFLD plus and PCOS exceeded that of girls with NAFLD alone, girls with PCOS alone and boys without NAFLD. Further, girls with NAFLD plus PCOS were more insulin resistant and had higher serum hsCRP and leptin levels than boys and other girls. Systolic blood pressure was, however, higher in boys than girls with or without a diagnosis of NAFLD or PCOS. Thus, the anthropometric and metabolic phenotype of adolescent girls with PCOS combined with NAFLD may characterize an increased risk of cardiovascular disease and type 2 diabetes mellitus, resembling that of adolescent males with NAFLD, but which exceeds that of other females or males without NAFLD. Whilst we did not find a direct androgen-association for this, the coincidence of PCOS and NAFLD in females may signify a higher risk of

nonalcoholic steatohepatitis (NASH)-associated cirrhosis than in females without the combination of PCOS and NAFLD^{8,50}.

We have demonstrated a degree of diagnostic overlap between NAFLD and PCOS, with more pronounced hepatic steatosis, adiposity and metabolic risk factors in adolescent girls with NAFLD combined with PCOS compared with other girls. A major strength of our study is that it derives from a well-characterised longitudinal community-based cohort with matched males. Limitations of our study are the absence of histologic or magnetic resonance imaging assessment of steatosis and a small sample size. However, liver biopsy is invasive and not appropriate in a community-based study of generally well adolescents. Furthermore, liver ultrasound is the most common diagnostic imaging method for diagnosing NAFLD and has been validated against histologic diagnosis of steatosis and metabolic outcomes⁴⁶⁻⁴⁸.

In conclusion, girls with NAFLD plus PCOS have adverse metabolic phenotypic characteristics comparable to those of boys with NAFLD but more pronounced than girls with NAFLD alone or PCOS alone. Obesity was the dominant characteristic of girls with NAFLD plus PCOS. NAFLD in adolescent girls was predicted by suprailiac skinfold thickness and a PCOS diagnosis. Girls with PCOS were nearly thrice as likely to have NAFLD than girls without PCOS. However, serum ALT, hsCRP, insulin resistance and raised total and free testosterone levels did not independently predict NAFLD in this population of adolescent girls once PCOS was accounted for. Our results are not sufficient to recommend screening for PCOS in females with NAFLD or vice versa, however it may be pertinent to focus hepatic, metabolic and reproductive health risk assessment on those

females diagnosed with NAFLD combined with PCOS. Further studies on early identification and metabolic risk mitigation, including liver morbidity in women with NAFLD combined with PCOS are required.

Acknowledgment: The authors thank the Raine Study participants and their families; They also thank the Raine Study team for cohort coordination and data collection. The National Health and Medical Research Council, the University of Western Australia, the Raine Medical Research Foundation, the University of Western Australia Faculty of Medicine, Dentistry, and Health Sciences, the Telethon Institute for Child Health Research, the Women's and Infant's Research Foundation and Curtin University are acknowledged for their support and funding of the Raine Study.

References

1. Ayonrinde OT, Olynyk JK, Beilin LJ, et al. Gender-specific differences in adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver disease. *Hepatology* 2011;53:800-809.
2. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. *Pediatrics* 2006;118:1388-1393.
3. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. *The New England Journal of Medicine* 2010;363:1341-1350.
4. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. *Gastroenterology* 2012;142:1592-1609.
5. Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. *Best Pract Res Clin Obstet Gynaecol* 2004;18:671-683.
6. Hart R, Doherty DA, Mori T, et al. Extent of metabolic risk in adolescent girls with features of polycystic ovary syndrome. *Fertil Steril* 2011;95:2347-2353.
7. Hart R, Doherty DA. The potential implications of a PCOS diagnosis on a woman's long-term health using data linkage. *The Journal of clinical endocrinology and metabolism*. 2015 Mar;100(3):911-919.
8. Setji TL, Holland ND, Sanders LL, Pereira KC, Diehl AM, Brown AJ. Nonalcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2006;91:1741-1747.

9. Marchesini G, Brizi M, Bianchi G, Tomassetti, S. Bugianesi, E, Lenzi, M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. *Diabetes* 2001;50:1844-1850.
10. Baranova A, Tran TP, Bircerdinc A, Younossi ZM. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. *Aliment Pharmacol Ther.* 2011;33(7):801-814
11. Franks S. Polycystic ovary syndrome in adolescents. *Int J Obes (Lond)* 2008;32:1035-1041
12. ESHRE/ASRM. ESHRE/ASRM Rotterdam Consensus Meeting Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). *Hum Reprod* 2004;19:41-47.
13. Hart R, Norman R. Polycystic ovarian syndrome--prognosis and outcomes. *Best Pract Res Clin Obstet Gynaecol* 2006;20:751-778.
14. Zawadzki JK, Dunaif A 1992 Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds. *Polycystic ovary syndrome*. Boston: Blackwell Scientific; 377–384
15. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. *Hum Reprod* 2010;25:544-551.
16. Dale PO, Tanbo T, Vaaler S, Abyholm T. Body weight, hyperinsulinemia, and gonadotropin levels in the polycystic ovarian syndrome: evidence of two distinct populations. *Fertil Steril* 1992;58:487-491.
17. Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, Bodian C, Yeh HC, Futterweit W. Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. *Clinical Gastroenterology and Hepatology* 2007;5:496-501.

18. Cerda C, Perez-Ayuso RM, Riquelme A, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. *J Hepatol* 2007;47:412-417.
19. Targher G, Solagna E, Tosi F, et al. Abnormal serum alanine aminotransferase levels are associated with impaired insulin sensitivity in young women with polycystic ovary syndrome. *J Endocrinol Invest* 2009;32:695-700.
20. Schwimmer JB, Khorram O, Chiu V, Schwimmer WB. Abnormal aminotransferase activity in women with polycystic ovary syndrome. *Fertil Steril* 2005;83:494-497.
21. Vassilatou E, Lafoyianni S, Vryonidou A, et al. Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. *Hum Reprod* 2010;25:212-220.
22. Lerchbaum E, Gruber HJ, Schwetz V, et al. Fatty liver index in polycystic ovary syndrome. *Eur J Endocrinol* 2011;165:935-943.
23. Zheng RH, Ding CF. Prevalence of nonalcoholic fatty liver disease in patients with polycystic ovary syndrome: a case-control study. *Zhonghua Fu Chan Ke Za Zhi* 2008;43:98-101.
24. Zueff LF, Martins WP, Vieira CS, Ferriani RA. Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome. *Ultrasound Obstet Gynecol.* 2012;39(3):341-347.
25. Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in nonobese patients with polycystic ovarian disease. *J Clin Endocrinol Metab* 1983;57:356-359.
26. Markou A, Androulakis, II, Mourmouris C, et al. Hepatic steatosis in young lean insulin resistant women with polycystic ovary syndrome. *Fertil Steril* 2010;93:1220-1226.

27. Brzozowska MM, Ostapowicz G, Weltman MD. An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome. *J Gastroenterol Hepatol*. 2009 Feb;24(2):243-247
28. Corbould A, Bhathal PS, Dixon JB, et al. Interrelationships of serum androgens, omental adipose tissue metabolism, and nonalcoholic fatty liver disease in obese premenopausal women. *Metab Syndr Relat Disord* 2014;12:311-319
29. Baranova A, Tran TP, Afendy A, et al. Molecular signature of adipose tissue in patients with both non-alcoholic fatty liver disease (NAFLD) and polycystic ovarian syndrome(PCOS). *J Transl Med*. 2013;11:133
30. Schwimmer JB, Behling C, Newbury R, et al. Histopathology of pediatric nonalcoholic fatty liver disease. *Hepatology*. 2005;42(3):641-649
31. Vassilatou E. Nonalcoholic fatty liver disease and polycystic ovary syndrome. *World J Gastroenterol*. 2014 Jul 14;20(26):8351-8363
32. Manneras-Holm L, Leonhardt H, Kullberg J, et al. Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. *J Clin Endocrinol Metab* 2011;96:E304-311.
33. Fox R, Corrigan E, Thomas PG, Hull MG. Oestrogen and androgen states in oligo-amenorrhoeic women with polycystic ovaries. *Br J Obstet Gynaecol* 1991;98:294-299.
34. Brand JS, van der Tweel I, Grobbee DE, Emmelot-Vonk MH, van der Schouw YT. Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. *Int J Epidemiol* 2011;40:189-207.

35. Stener-Victorin E, Holm G, Labrie F, et al. Are there any sensitive and specific sex steroid markers for polycystic ovary syndrome? *J Clin Endocrinol Metab* 2010;95:810-819.
36. Kauffman RP, Baker TE, Baker V, Kauffman MM, Castracane VD. Endocrine factors associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome: do androgens play a role? *Gynecol Endocrinol* 2010;26:39-46.
37. Jayagopal V, Kilpatrick ES, Jennings PE, Hepburn DA, Atkin SL. The biological variation of testosterone and sex hormone-binding globulin (SHBG) in polycystic ovarian syndrome: implications for SHBG as a surrogate marker of insulin resistance. *J Clin Endocrinol Metab* 2003;88:1528-1533.
38. Glueck CJ, Morrison JA, Daniels S, Wang P, Stroop D. Sex hormone-binding globulin, oligomenorrhea, polycystic ovary syndrome, and childhood insulin at age 14 years predict metabolic syndrome and class III obesity at age 24 years. *J Pediatr* 2011;159:308-313 e302.
39. Shin JY, Kim SK, Lee MY, et al. Serum sex hormone-binding globulin levels are independently associated with nonalcoholic fatty liver disease in people with type 2 diabetes. *Diabetes Res Clin Pract* 2011;94:156-162.
40. Tian GX, Sun Y, Pang CJ, et al. Oestradiol is a protective factor for non-alcoholic fatty liver disease in healthy men. *Obes Rev* 2012;13:381-387.
41. Baillargeon JP, Carpentier AC. Brothers of women with polycystic ovary syndrome are characterised by impaired glucose tolerance, reduced insulin sensitivity and related metabolic defects. *Diabetologia* 2007;50:2424-2432.
42. Coviello AD, Sam S, Legro RS, Dunaif A. High prevalence of metabolic syndrome in first-degree male relatives of women with polycystic ovary syndrome is related to high rates of obesity. *J Clin Endocrinol Metab* 2009;94:4361-4366.

43. Macdonald W, Newnham J, Gurrin L, Evans S. Effect of frequent prenatal ultrasound on birthweight: follow up at 1 year of age. Western Australian Pregnancy Cohort (Raine) Working Group. *Lancet* 1996;348:482.
44. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. *BMJ* 2000;320:1240-1243.
45. Zimmet P, Alberti G, Kaufman F, et al. The metabolic syndrome in children and adolescents. *Lancet* 2007;369:2059-2061.
46. Hamaguchi M, Kojima T, Itoh Y, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. *Am J Gastroenterol* 2007;102:2708-2715.
47. Liu KH, Chan YL, Chan WB, Kong WL, Kong MO, Chan JC. Sonographic measurement of mesenteric fat thickness is a good correlate with cardiovascular risk factors: comparison with subcutaneous and preperitoneal fat thickness, magnetic resonance imaging and anthropometric indexes. *Int J Obes Relat Metab Disord* 2003;27:1267-1273.
48. Kim SK, Kim HJ, Hur KY, et al. Visceral fat thickness measured by ultrasonography can estimate not only visceral obesity but also risks of cardiovascular and metabolic diseases. *Am J Clin Nutr* 2004;79:593-599.
49. Hickey M, Doherty DA, Atkinson H, et al. Clinical, ultrasound and biochemical features of polycystic ovary syndrome in adolescents: implications for diagnosis. *Hum Reprod* 2011;26:1469-1477.
50. Tan S, Bechmann LP, Benson S, et al. Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome. *J Clin Endocrinol Metab* 2010;95:343-348.

Author Manuscript

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Ayonrinde, OT;Adams, LA;Doherty, DA;Mori, TA;Beilin, LJ;Oddy, WH;Hickey, M;Sloboda, DM;Olynyk, JK;Hart, R

Title:

Adverse metabolic phenotype of adolescent girls with non-alcoholic fatty liver disease plus polycystic ovary syndrome compared with other girls and boys

Date:

2016-05-01

Citation:

Ayonrinde, O. T., Adams, L. A., Doherty, D. A., Mori, T. A., Beilin, L. J., Oddy, W. H., Hickey, M., Sloboda, D. M., Olynyk, J. K. & Hart, R. (2016). Adverse metabolic phenotype of adolescent girls with non-alcoholic fatty liver disease plus polycystic ovary syndrome compared with other girls and boys. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 31 (5), pp.980-987. <https://doi.org/10.1111/jgh.13241>.

Persistent Link:

<http://hdl.handle.net/11343/291220>